Visualization of positive and negative sense viral RNA for probing the mechanism of direct-acting antivirals against hepatitis C virus [PDF]
, 2019 RNA viruses are highly successful pathogens and are the causative agents for many important diseases. To fully understand the replication of these viruses it is necessary to address the roles of both positive-strand RNA ((+)RNA) and negative-strand RNA ((
Bassit, Leda C +13 more
core +2 more sources
Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. [PDF]
, 2017 BACKGROUND & AIM: concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following directly acting antiviral (DAA) therapy in cirrhotic patients with a prior complete oncological response have been raised. Data regarding the impact of
Angeli, Paolo +16 more
core +1 more source
New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
Journal of Investigative Medicine High Impact Case Reports, 2015 The combination therapy of ledipasvir/sofosbuvir was approved by the Food and Drug Administration in 2014 for the treatment of chronic hepatitis C. Although hyperglycemia is not well known to occur with its use, we present 2 cases of new-onset diabetes ...
Resmi Premji MD +3 more
doaj +1 more source
Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. [PDF]
, 2016 HCV is the leading cause of death from liver disease and is the most common indication for a liver transplantation. Although HCV is a widespread health problem, disease management is particularly challenging in several key subpopulations, including liver
Burra, Patrizia +2 more
core +1 more source
Balkan Medical Journal, 2023 Background: Treatment using direct-acting antivirals provides high rates of sustained virologic response and a favorable safety profile for patients with chronic hepatitis C virus infection.
Ayşe Serra Artan +13 more
doaj +1 more source
AA. VV., Los Dominicos y el Nuevo Mundo, Actas del III Congreso Internacional, ed. Deimos, Madrid 1991, 852 pp., 17 x 24. [RECENSIÓN] [PDF]
, 2017 BACKGROUND: Treatment of genotype 1 hepatitis C virus (HCV) infection with combination direct acting anti-virals is associated with very high rates of sustained virological response (SVR).
Afdhal +33 more
core +2 more sources
Pharmacokinetic interactions between simeprevir and ledipasvir in treatment naive hepatitis C virus genotype 1-Infected patients without cirrhosis treated with a simeprevir-sofosbuvir-ledipasvir regimen [PDF]
, 2017 Interactions between simeprevir (hepatitis C virus [HCV] NS3/4A protease inhibitor) and ledipasvir (HCV NS5A replication complex inhibitor) were investigated in treatment-naive HCV genotype 1-infected patients without cirrhosis, treated with simeprevir ...
Beumont, Maria +12 more
core +2 more sources
Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis [PDF]
, 2016 UNLABELLED: Prisoners have a high prevalence of hepatitis C virus (HCV), but case-finding may not have been cost-effective because treatment often exceeded average prison stay combined with a lack of continuity of care. We assessed the cost-effectiveness
Brew, Iain F. +10 more
core +3 more sources
Hepatitis C virus resistance to the new direct-acting antivirals [PDF]
, 2016 Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella +2 more
core +1 more source
Viruses, 2015 Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries.
Bruno Roche +3 more
doaj +1 more source